Fran Gregory, PharmD, MBA has been named Vice President of Emerging Therapies for Cardinal Health.
In this role, she will be responsible for responsible for cell & gene therapies and biosimilars.
“Fran began her career initiating one of the largest specialty pharmacies in the country. She followed that accomplishment with bringing the first cell & gene therapy in the world to patients.
“Most recently, Fran developed and launched several of the most successful biosimilars in the US. She has a passion for complex, life-changing medicines and excels at developing and growing innovative business units. Fran is an industry expert in reimbursement, value-based pharmaceutical contracting, HEOR, and leading successful teams.”
Allogene Therapeutics, a San Francisco clinical-stage biotech pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, has appointed Timothy Moore as Executive Vice President, Chief Technical Officer effective April 24, 2023.
Moore succeeds Alison Moore, Ph.D., who intends to serve as a consultant to Allogene.
“The selection of Mr. Moore, the former Executive Vice President, Technical Operations of Kite Pharma responsible for the global development of two of the most commercially successful autologous CAR T manufacturing processes in the industry, reinforces the company’s mission to being the first to bring an AlloCAR T product to market,” says Allogene Therapeutics.
“As we look ahead to what could be the industry’s first regulatory submission for an allogeneic CAR T product, we are thrilled to welcome Tim Moore to our team.”
Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations. He was Executive Vice President, Technical Operations at Kite Pharma (now a Gilead company) from 2016 to 2019, where he was responsible for the process development, manufacturing, quality and supply chain for Yescarta, the first FDA approved CAR T therapy for the treatment of non-Hodgkin lymphoma.
He and his team also developed the manufacturing process for Kite’s second FDA approved autologous CAR T therapy, Tecartus. Mr. Moore expanded biopharmaceutical operations to serve and support the US and EU as well as key partners in Asia. Most recently, he continued his effort of advancing the field of engineered cell manufacturing as Chief Operating Officer of Instil Bio, and President and Chief Operating Officer of PACT Pharma.
Prior to Kite, Moore served as the Senior Vice President, Head of Global Technical Operations – Biologics of Genentech, Inc. and as a member of the Genentech Executive Committee where he oversaw global leadership for more than 7,500 professionals across 10 internal sites and over 37 contract manufacturing organizations, as well as global manufacturing and end-to-end quality supply performance of more than 20 biological product families.
He also serves as a Board member for Cerus and BioLife Solutions. Mr. Moore received a B.S. in Chemical Engineering from Tulsa University and a M.S. in Engineering Management from Northwestern University.
Sanofi has appointed Elisabeth Moreno, former French Minister for Gender Equality, Diversity and Equal opportunities, to its Diversity, Equity and Inclusion (DE&I) Board for the next three years.
Created in 2022 at the executive level with the aim to accelerate Sanofi’s DE&I agenda globally, this advisory council’s role is to support Sanofi’s DE&I strategy, to monitor progress on the company’s 2025 goals and to advise on how to amplify its impact in this space.
Moreno has worked in various industries and fast paced international environments, such as France Télécom (now Orange), Dell and Lenovo. One of her latest positions was Lead for the African continent organization at Hewlett Packard.
In 2020, she was appointed by the President of the French Republic, Emmanuel Macron, as Minister for Gender Equality, Diversity and Equal opportunities in the French government, where she successfully introduced a bill intended to protect victims of domestic violence and another one to promote women economic emancipation and a law to protect victims of conversion therapies. In 2021, she launched a platform to fight discrimination together with the Advocate of Human Rights.
Moreno joins social entrepreneur Caroline Casey, thought-leader Dr. Rohini Anand, Sanofi CEO Paul Hudson and other Sanofi members on the DE&I Board.
Nick Kozauer, M.D. has joined Biohaven’s executive leadership team as Senior Vice President for Clinical Development and Regulatory Strategy.
Dr. Kozauer comes to Biohaven after an accomplished career at the US Food and Drug Administration (FDA) where he served in positions of increasing responsibility, most recently as Director of the Division of Neurology 2 in the Office of New Drugs.
During his tenure at the FDA, Dr. Kozauer led the division responsible for the regulation of all Investigational New Drug (IND) applications, New Drug Applications (NDAs), and Biological Licensing Applications (BLAs) for drugs being developed and/or approved for the treatment of neuroimmunologic conditions, epilepsies, migraine, stroke, traumatic brain injury, inner ear disorders, and other products.
Prior to joining the FDA, Dr. Kozauer worked in academia at the Johns Hopkins Memory Center at the Copper Ridge Institute where he oversaw clinical care of patients with Alzheimer's disease and other dementias, and in private practice focusing on complex neuropsychiatric conditions. Dr. Kozauer completed his residency and fellowship training at Georgetown University Medical Center and Johns Hopkins, respectively, and received his M.D. from Rutgers-New Jersey Medical School.
Epigenomic editing company Tune Therapeutics has introduced two members to its leadership team: Chief Scientific Officer, Derek Jantz, Ph.D., and General Counsel, Zachary Hale, J.D.
Dr. Jantz comes to Tune with deep expertise in developing cell and gene therapeutic candidates through the use of innovative genomic technologies.
Tune’s genetic tuning platform, TEMPO, enables precise and durable changes to gene expression without risking permanent, off-target mutations across the genome. Dr. Jantz will spearhead the development of Tune’s transformative genetic tuning platform, which has the potential to target a broad range of common, complex, and multigenic diseases.
Dr. Jantz co-founded Precision BioSciences in 2006 as co-inventor of a novel method for modifying the DNA-recognition properties of the I-Crel homing endonuclease, which in turn provided the foundation for the ARCUS genome editing platform. At Precision, he led the development of allogeneic CAR T and in vivo editing platforms, overseeing all research teams and serving on the board of directors. Dr. Jantz holds more than 50 patents relating to gene editing, gene therapy, and cancer immunotherapy, and is the author of more than a dozen gene-editing publications.
As Tune’s new General Counsel, Zach Hale will oversee all of Tune’s legal affairs.
Hale joins the company after over a decade of specialized legal work with biotechnology startups. He previously served as Senior Vice President and Deputy General Counsel at Juno Therapeutics, and before that was a corporate attorney at the international law firm Latham & Watkins LLP. He received his J.D. from Yale Law School and his B.A. summa cum laude from Harvard.
